LTA4 hydrolase inhibitor pharmaceutical compositions and methods

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514567, A61K 3124, A61K 31195

Patent

active

057234922

ABSTRACT:
The present invention provides compounds of the formula Ar.sup.1 --Q--Ar.sup.2 --Y--R--Z and pharmaceutically acceptable salts thereof wherein Ar.sup.1 and Ar.sup.2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB.sub.4 production, such as psoriasis, ulcerative colitis, IBD and asthma.

REFERENCES:
patent: 2831859 (1958-04-01), Kindler et al.
patent: 4010272 (1977-03-01), Loewe et al.
patent: 4038319 (1977-07-01), Pinhas
patent: 4339576 (1982-07-01), Zenitz
patent: 4417052 (1983-11-01), Zenitz
patent: 4803227 (1989-02-01), Brandes et al.
patent: 4829068 (1989-05-01), Brandes et al.
patent: 5192786 (1993-03-01), Press et al.
patent: 5432168 (1995-07-01), Brandes
J. Evans et al., Prostaglandins, Leukotriens and Medicine, vol. 23, 1986, pp.167-171.
R. Kikumoto et al., J. Med. Chem., vol. 24, No. 2, 1981, pp.145-148.
Chemical Abstracts, vol. 122, No. 15 Abst. No. 187596b (Apr. 10, 1995).
L.J. Brandes et al., Biochem. Biophys. Res. Commun., vol. 179, No. 3, pp. 1297-1304 (Sep. 30, 1991).
M. Poirot et al.,Biochem. Pharamcol., vol. 40,No. 3,pp. 425-429A (Aug. 1, 1990).
C. Chailleux et al.,Mol. Pharmacol., vol. 44, No. 2,pp. 324-327 (Aug. 2, 1993).
L.J. Brandes et al., J. Clin. Oncol., vol. 12, No. 6 pp. 1281-1290 (Jun. 6, 1994).
L. Brandes et al. Chem. Abstr. 115:64790h, "Treatment of ulcer disorders of the gastrointestinal tract with diphenylmethane derivatives" (1991).
A. Fargin et al. Chem.-Biol. Interactions, 66, 101-109 (1988), "Further Evidence For a Biological Role of Anti-Estrogen-Binding Sites in Mediating the Growth Inhibitory Action of Diphenylmethane Derivatives".
K. Kindler et al. Ann die Chemie (617), 25-54 (1958), "Katalytisch-Specifische Kondensationen Mit Dihalogeniden, I".
R. Labaudiniere et al. J. Med. Chem., 35, 3170-3179 (1992), Hydrolase Inhibitors to LTB, Receptor Antagonists".
R. Labaudiniere et al. J. Med. Chem., 35, 3156-3169 (1992), LTA, Hydrolase Inhibitors".
F. Lakhdar-Ghazal et al. Biochemical Pharmacology 42 (11), 2099-2105 (1991), "Interactions Between Trypanocidal Drugs and Membrane Phospholipids".
D. Nardi et al. II Farmaco-Ed. Sc., -- vol. 20(8) 557-565 (1965), "Nuovi Sali Ammonici Quaternari Ad Attivita Ganglioplegica E. Ipotensiva".
A. Oda et al. Chem. Abstr. 119:88896f, "Phenoxyethylamines as bactericides for crops" (1993).
M. Protiva et al. Chem. Iistech 43, 254-257 (1949) "Antihistaminove latky XIV.*) Basicke ethery odvozene od 2-a 4-hydroxydifenylsulfidu, 2-hydroxydifenyletheru a 2-hydroxydifenylaminu".
W. Yuan et al. J. Med. Chem., 36, 211-220 (1993), "Development of Selective Tight-Binding Inhibitors of Leukotriene A.sub.4 Hydrolase".
W. Yuan et al. J. Am. Chem. Soc. 114, 6552-6553 (1992), "Novel Tight-Binding Inhibitors of Leukotriene A.sub.4 Hydrolase".
Karrer, Chemical Abstracts, vol. 114, Abstract No. 185024, 1990.
Sakamoto et al, Chemical Abstracts, vol. 119, Abstract No. 175905, 1993.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

LTA4 hydrolase inhibitor pharmaceutical compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with LTA4 hydrolase inhibitor pharmaceutical compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LTA4 hydrolase inhibitor pharmaceutical compositions and methods will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2248053

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.